Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press149410.17650/1726-9776-2021-17-4-136-150REVIEWSОБЗОРЫModern possibilities of application 99mTc-labeled prostate-specific membrane antigen ligands in prostate cancerСовременные возможности применения радиофармпрепаратов на основе лигандов к простатспецифическому мембранному антигену, меченных 99mTc, при раке предстательной железыhttps://orcid.org/0000-0002-4282-0192LeontyevA. V.ЛеонтьевА. В.
Russian Federation

Alexey V. Leontyev - cand. of med. sci., Head of Nuclear Medicine Department of Moscow Research Oncology Institute named after P.A. Herzen – branch of “National Medical Research Center of Radiology” of the Ministry of Health of the Russian Federation.

3 2nd Botkinskiy Proezd, Moscow 125284.

Леонтьев Алексей Викторович - кандидат медицинских наук, заведующий отделением радионуклидной диагностики.

125284 Москва, 2-й Боткинский проезд, 3.

aleksleont@yandex.ruhttps://orcid.org/0000-0002-8905-4202KhalimonA. I.ХалимонА. И.
Russian Federation

Alexander I. Khalimon - radiologist of CT and MRI Department of Moscow Research Oncology Institute named after P.A. Herzen – branch of «National Medical Research Radiological Center» of the Ministry of Healthcare of Russia.

3 2nd Botkinskiy Proezd, Moscow 125284.

Халимон Александр Игоревич - врач-рентгенолог отделения КТ и МРТ.

125284 Москва, 2-й Боткинский проезд, 3.

markyhaws@gmail.comhttps://orcid.org/0000-0002-3508-1782KulievM. T.КулиевМ. Т.
Russian Federation

Magomed T. Kuliev - nuclear medicine physician of Nuclear Medicine Department of Moscow Research Oncology Institute named after P.A. Herzen – branch of “National Medical Research Center of Radiology” of the Ministry of Health of the Russian Federation.

3 2nd Botkinskiy Proezd, Moscow 125284.

Кулиев Магомед Темирланович - врач-радиолог отделения радионуклидной диагностики.

125284 Москва, 2-й Боткинский проезд, 3.

kul502@yandex.ruhttps://orcid.org/0000-0002-8971-4442GovaleshkoA. Y.ГовалешкоА. Ю.
Russian Federation

Anastasia Yu. Govaleshko - Resident of Nuclear Medicine Department of Moscow Research Oncology Institute named after P. A. Herzen – branch of “National Medical Research Center of Radiology” of the Ministry of Health of the Russian Federation.

3 2nd Botkinskiy Proezd, Moscow 125284.

Говалешко Анастасия Юрьевна - клинический ординатор отделения радионуклидной диагностики.

125284 Москва, 2-й Боткинский проезд, 3.

govald.an@gmail.comhttps://orcid.org/0000-0001-8784-8415KaprinA. D.КапринА. Д.
Russian Federation

4 Koroleva St., Obninsk 249031.

249031 Обнинск, ул. Королева, 4.

https://orcid.org/0000-0002-9854-7375KrasheninnikovA. A.КрашенинниковА. А.
Russian Federation

Alexey A. Krasheninnikov - junior researcher, Department of reproductive organs and urinary tract of Moscow Research Oncology Institute named after P. A. Herzen – branch of “National Medical Research Center of Radiology” of the Ministry of Health of the Russian Federation.

3 2nd Botkinskiy Proezd, Moscow 125284.

Крашенинников Алексей Артурович - младший научный сотрудник отдела репродуктивных органов и мочевыводящих путей.

125284 Москва, 2-й Боткинский проезд, 3.

krush07@yandex.ruhttps://orcid.org/0000-0002-4171-6211NyushkoK. M.НюшкоК. М.
Russian Federation

Kirill M. Nyushko - doc. of med. sci., leading researcher of Department of Oncourology of Moscow Research Oncology Institute named after P. A. Herzen – branch of “National Medical Research Center of Radiology” of the Ministry of Health of the Russian Federation, leading researcher of Department of Oncourology of N. Lopatkin Scientific Research Institute of Urology and Interventional Radiology - branch of the National Medical Research Radiologiсal Center of the Ministry of Health of Russian Federation, Professor of Department of oncology of medical institute of Continuing Education Moscow State University of Food Production of Russia.

3 2nd Botkinskiy Proezd, Moscow 125284; 11 Volokolamskoe Shosse, Moscow 125080; Build. 1, 51 3rd Parkovaya St., Moscow 105425.

Нюшко Кирилл Михайлович - доктор медицинских наук, ведущий научный сотрудник отделения онкоурологии МНИОИ им. П.А. Герцена; ведущий научный сотрудник отдела онкоурологии НИИ урологии и интервенционной радиологии им. Н.А. Лопаткина; профессор кафедры онкологии медицинского института непрерывного образования МГУПП.

125284 Москва, 2-й Боткинский проезд, 3; 125080 Москва, Волоколамское шоссе, 11; 105425 Москва, 3-я Парковая ул., 51, стр. 1.

kirandja@yandex.ruhttps://orcid.org/0000-0002-2209-3020KalpinskiyA. S.КалпинскийА. С.
Russian Federation

Aleksey S. Kalpinskiy - cand. of med. sci., senior researcher, Department of reproductive organs and urinary tract of Moscow Research Oncology Institute named after P.A. Herzen – branch of “National Medical Research Center of Radiology” of the Ministry of Health of the Russian Federation.

3 2nd Botkinskiy Proezd, Moscow 125284.

Калпинский Алексей Сергеевич - кандидат медицинских наук, старший научный сотрудник отдела репродуктивных органов и мочевыводящих путей.

125284 Москва, 2-й Боткинский проезд, 3.

dr.Kalpinskiytrial@gmail.comhttps://orcid.org/0000-0002-3398-4128AlekseevB. Ya.АлексеевБ. Я.
Russian Federation

Boris Ya. Alekseev - doc. of med. sci., professor, senior researcher, Deputy of General director of scientific affairs “National Medical Research Center of Radiology” of the Ministry of Health of the Russian Federation, Head of Department of oncology of medical institute of Continuing Education Moscow State University of Food Production of Russia.

4 Koroleva St., Obninsk 249031; 11 Volokolamskoe Shosse, Moscow 125080.

Алексеев Борис Яковлевич - доктор медицинских наук, профессор, заместитель генерального директора по научной работе НМИЦ радиологии МЗ РФ; заведующий кафедрой онкологии медицинского института непрерывного образования МГУПП.

249031 Обнинск, ул. Королева, 4; 125080 Москва, Волоколамское шоссе, 11.

byalekseev@mail.ruP.A. Hertzen Moscow Oncology Research Institute — branch of the National Medical Research Radiological Center, Ministry of Health of RussiaМосковский научно-исследовательский онкологический институт им. П.А. Герцена — филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава РоссииNational Medical Research Radiological Center, Ministry of Health of RussiaНациональный медицинский исследовательский центр радиологии Минздрава РоссииMedical Institute of Continuing Education, Moscow State University of Food Production3Медицинский институт непрерывного образования ФГБОУ ВО «Московский государственный университет пищевых производств»N.A. Lopatkin Research Institute of Urology and Interventional Radiology — branch of the National Medical Research Radiological Center, Ministry of Health of RussiaНаучно-исследовательский институт урологии и интервенционной радиологии им. Н.А. Лопаткина — филиал ФГБУ «Национальный медицинский исследовательский центр радиологии Минздрава РоссииNational Medical Research Radiological Center, Ministry of Health of RussiaНациональный медицинский исследовательский центр радиологии» Минздрава РоссииMedical Institute of Continuing Education, Moscow State University of Food ProductionМедицинский институт непрерывного образования ФГБОУ ВО «Московский государственный университет пищевых производств»1012202117413615024092021191220212021https://oncourology.abvpress.ru/oncur/article/view/1494

This article presents a modern possibilities and future path of prostate-specific membrane antigen (PSMA) radiopharmacuticals labeled by 99mTc, that is the most popular isotope using in conventional nuclear medicine. The main advantages and disadvantages of SPECT/CT with these radiopharmaceuticals in different phases of prostate cancer continuum have been analyzed. Results of research diagnostic sensitivity of 99mTc-PSMA SPECT/CT including comparison with 68Ga-PSMA PET/CT and conventional modality such as MRI and bone scan are presented. The prerequisites of application 99mTc-labeled PSMA ligands in PSMA-guided surgery, methodology of PSMA-guided surgery and foreign authors application experience are presented in this article too.

В статье представлены современные тенденции и перспективы применения радиофармпрепаратов на основе лигандов к простатспецифическому мембранному антигену (ПСМА), меченных наиболее широко используемым в традиционной радионуклидной диагностике радиоизотопом 99mTc. Проанализированы основные достоинства и недостатки применения этих радиофармпрепаратов в рамках гибридной визуализации (ОФЭКТ/КТ) у пациентов на различных этапах развития рака предстательной железы. Представлены результаты исследований, в которых оценивались диагностические возможности ОФЭКТ/КТ с радиофармпрепаратами данной группы, в том числе в сравнении с ПЭТ/КТ с 68Ga-nCMA и традиционно применяемыми методиками визуализации (магнитно-резонансной томографией, остеосцинтиграфией). Рассмотрены предпосылки к использованию радиофармпрепаратов на основе меченных 99mTc лигандов к ПСМА в радионавигационной хирургии, описаны методика выполнения, а также опыт применения данной технологии зарубежными авторами.

prostate cancersalvage lymph node dissectionradioguided surgeryprostate-specific membrane antigen99mTc-PSMASPECT/CTPET/CTрак предстательной железыспасительная лимфаденэктомиярадионавигационная хирургияпростатспецифический мембранный антиген99mTc-ПСМАОФЭКТ/КТПЭТ/КТMalignant tumors in Russia in 2019 (morbidity and mortality). Eds.: A.D. Kaprin, V.V. Starinskiy, A.O Shachzadova. Moscow: MNIOI im. P.A. Gertsena -filial FGBU “NMITS radiologii” Minzdrava Rossii, 2020. 239 p. (In Russ.).Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020. 239 с.Носов Д.А., Волкова М.И., Гладков О.А. и др. Практические рекомендации по лекарственному лечению рака предстательной железы. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2020 (том 10).33. DOI: 10.18027/2224-5057-2020-10-3s2-33.Israeli R.S., Powell C.T., Fair W.R., Heston W.D. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993;53(2):227-30.Silver D.A., Pellicer I., Fair W.R. et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3(1):81-5.Barinka C., Sacha P., Sklenar J. et al. Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity. Protein Sci 2004;13 (6):1627-35. DOI: 10.1110/ps.04622104.Cardinale J., Martin R., Remde Y. et al. Procedures for the GMP-compliant production and quality control of [(18)F] PSMA-1007: a next generation radiofluorinated tracer for the detection of prostate cancer. Pharmaceuticals (Basel) 2017;10(4):77. DOI: 10.3390/ph10040077.Alam I.S., Steinberg I., Vermesh O. et al. Emerging intraoperative imaging modalities to improve surgical precision. Mol Imaging Biol 2018;20(5):705-15. DOI: 10.1007/s11307-018-1227-6.Povoski S.P., Neff R.L., Mojzisik C.M. et al. A comprehensive overview of radioguided surgery using gamma detection probe technology. World J Surg Oncol 2009;7:11. DOI: 10.1186/1477-7819-7-11.Bugby S.L., Lees J.E., Perkins A.C. Hybrid intraoperative imaging techniques in radioguided surgery: present clinical applications and future outlook. Clin Transl Imaging 2017;5(4):323-41. DOI: 10.1007/s40336-017-0235-x.Orsaria P., Chiaravalloti A., Fiorentini A. et al. PET probe-guided surgery in patients with breast cancer: proposal for a methodological approach. In vivo 2017;31(1):101-10. DOI: 10.21873/invivo.11031.Werner P., Neumann C., Eiber M. et al. [99cmTc]Tc-PSMA-I&S-SPECT/CT: experience in prostate cancer imaging in an outpatient center. EJNMMI Res 2020;10:45.Su H.C., Zhu Y., Ling G.W. et al. Evaluation of 99mTc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapse. Asian J Androl 2017;19(3):267-71. DOI: 10.4103/1008-682X.192638.Lawal I.O., Ankrah A.O., Mokgoro N.P. et al. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: a comparative analysis with Ga-68 PSMA PET/CT. Prostate 2017;77(11):1205-12. DOI: 10.1002/pros.23379.Albalooshi B., Al sharhan M., Bagheri F. et al. Direct comparison of 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT in patients with prostate cancer. Asia Ocean J Nucl Med Biol 2020;8(1):1-7. DOI: 10.22038/aojnmb.2019.43943.1293.Langsteger W., Rezaee A., Pirich C., Beheshti M. 18F-NaF-PET/CT and 99mTc-MDP bone scintigraphy in the detection of bone metastases in prostate cancer. Semin Nucl Med 2016;46(6):491-501. DOI: 10.1053/j.semnuclmed.2016.07.003.Lengana T., Lawal I.O., Boshomane T.G. et al. 68Ga-PSMA PET/CT replacing bone scan in the initial staging of skeletal metastasis in prostate cancer: a fait accompli? Clin Genitourin Cancer 2018;16(5):392-401. DOI: 10.1016/j.clgc.2018.07.009.Heidenreich A., Bellmunt J., Bolla M. et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59(1):61-71. DOI: 10.1016/j.eururo.2010.10.039.Mottet N., van den Bergh R.C.N., Briers E. et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer - 2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2021;79(2):243-62. DOI: 10.1016/j.eururo.2020.09.042.Tulsyan S., Das C.J., Tripathiet M. et al. Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for staging of high-risk prostate cancer68Ga-PSMA PET and MRI in prostate cancer. Nucl Med Commun 2017;38(12):1094-102. DOI: 10.1097/MNM.0000000000000749.Hofman M.S., Lawrentschuk N., Franci-set R.J. et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 2020;395(10231):1208-16. DOI: 10.1016/S0140-6736(20)30314-7.Afshar-Oromieh A., Zechmann C.M., Malcher A. et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014;41(1):11-20. DOI: 10.1007/s00259-013-2525-5.Morigi J.J., Stricker P.D., van Leeuwen P.J. et al. Prospective comparison of 18Ffluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med 2015;56(8):1185-90. DOI: 10.2967/jnumed.115.160382.Moghul M., Somani B., Lane T. et al. Detection rates of recurrent prostate cancer: 68gallium (Ga)-labelled prostatespecific membrane antigen versus choline PET/CT scans. A systematic review. Ther Adv Urol 2019;11:1756287218815793. DOI: 10.1177/1756287218815793.Briganti A., Giannarini G., Karnes R.J. et al. What evidence do we need to support the use of extended pelvic lymph node dissection in prostate cancer? Eur Urol 2015;67(4):597-8. DOI: 10.1016/j.eururo.2014.09.025.Harke N.N., Godes M., Wagner C. et al. Fluorescence-supported lymphography and extended pelvic lymph node dissection in robot-assisted radical prostatectomy: a prospective, randomized trial. World J Urol 2018;36(11):1817-23. DOI: 10.1007/s00345-018-2330-7.Grivas N., Wit E.M.K., Kuusk T. et al. The impact of adding sentinel node biopsy to extended pelvic lymph node dissection on biochemical recurrence in prostate cancer patients treated with robot-assisted radical prostatectomy. J Nucl Med 2018;59(2):204-9. DOI: 10.2967/jnumed.117.195644.Muck A., Langesberg C., Mugler M. et al. Clinical outcome of patients with lymph node-positive prostate cancer following radical prostatectomy and extended sentinel lymph node dissection. Urol Int 2015;94(3):296-306. DOI: 10.1159/000365011.Eiber M., Fendler W.P., Rowe S.P. et al. Prostate-specific membrane antigen ligands for imaging and therapy. J Nucl Med 2017;58(Suppl 2):67s-76s. DOI: 10.2967/jnumed.116.186767.Nagaya T., Nakamura Y.A., Choyke P.L., Kobayashi H. Fluorescence-guided surgery. Front Oncol 2017;7:314. DOI: 10.3389/fonc.2017.00314.Bravi C.A., Fossatia N., Gandaglia G. et al. Long-term outcomes of salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy: not as good as previously thought. Eur Urol 2020;78(5):661-9. DOI: 10.1016/j.eururo.2020.06.043.Claeys T., van Praet C., Lumen N. et al. Salvage pelvic lymph node dissection in recurrent prostate cancer: surgical and early oncological outcome. Biomed Res Int 2015;2015:198543. DOI: 10.1155/2015/198543.Porres D., Pfister D., Thissen A. et al. The role of salvage extended lymph node dissection in patients with rising PSA and PET/CT scan detected nodal recurrence of prostate cancer. Prostate Cancer Prostatic Dis 2017;20(1):85-92. DOI: 10.1038/pcan.2016.54.Knipper S., Tilki D., Mansholt J. et al. Metastases-yield and prostate-specific antigen kinetics following salvage lymph node dissection for prostate cancer: a comparison between conventional surgical approach and prostate-specific membrane antigen-radioguided surgery. Eur Urol Focus 2019;5(1):50-3. DOI: 10.1016/j.euf.2018.09.014.Robu S., Schottelius M., Eiber M. et al. Preclinical evaluation and first patient application of 99mTc-PSMA-I&S for SPECT imaging and radioguided surgery in prostate cancer. J Nucl Med 2017;58:235-42. DOI: 10.2967/jnumed.116.178939.Schottelius M., Wirtz M., Eiber M. et al. [(111)In]PSMA-I&T:expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery. EJNMMI Res 2015;5(1):68. DOI: 10.1186/s13550-015-0147-6.Maurer T., Robu S., Schottelius M. et al. 99mTc-based PSMA-radioguided surgery in recurrent prostate cancer. Eur Urol 2019;75(4):659-66. DOI: 10.1016/j.eururo.2018.03.013.Banerjee S.R., Pullambhatla M., Byun Y. et al. 68Ga-labeled inhibitors of prostatespecific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem 2010;53(14):5333-41. DOI: 10.1021/jm100623e.Weineisen M., Schottelius M., Simecek J. et al. 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med 2015;56(8):1169-76. DOI: 10.2967/jnumed.115.158550.Benz P., Oberhausen E., Berberich R. Monoclonal antibody BW431/26 labelled with technetium 99m and indium 111: an investigation of the biodistribution and the dosimetry in patients. Eur J Nucl Med 1991;18(10):813-6. DOI: 10.1007/BF00175060.Bunschoten A., van den Berg N.S., Valdes Olmos R.A. et al. Tracers applied in radioguided surgery. In: Radioguided surgery - current applications and innovation directions in clinical practice. Eds.: K. Hermann, O.E. Nieweg, S.P. Povosiki. Heidelberg, Germany: Springer International Publishing, 2016.Maurer T., Graefen M., van der Poel H. et al. Prostate-specific membrane antigen-guided surgery. J Nucl Med 2020;61(1):6-12. DOI: 10.2967/jnumed.119.232330.Kratzik C., Dorudi S., Schatzl M., Sinzinger H. Tc-99m-PSMA imaging allows successful radioguided surgery in recurrent prostate cancer. Hell J Nucl Med 2018;21(3):202-4. DOI: 10.1967/s002449910906.Rauscher I., Duwel C., Wirtz M. et al. Value of 111In-prostate-specific membrane antigen (PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up. BJU Int 2017;120(1):40-7. DOI: 10.1111/bju.13713.Horn T., Rauscher I., Eiber M. et al. PSMA-radioguided surgery in localised recurrent prostate cancer. Urologe A 2017;56(11):1417-23. DOI: 10.1007/s00120-017-0516-z.Van Leeuwen F.W., van der Poel H.G. Surgical guidance in prostate cancer: “from molecule to man” translations. Clin Cancer Res 2016;22(6):1304-6. DOI: 10.1158/1078-0432.CCR-15-2575.Jones A.D., Wilton J.C. Can intraoperative fluorescence play a significant role in hepatobiliary surgery? Eur J Surg Oncol 2017;43(9):1622-7. DOI: 10.1016/j.ejso.2017.02.015.Chen Y., Pullambhatla M., Banerjee S.R. et al. Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen. Bioconjug Chem 2012;23(12):2377-85. DOI: 10.1021/bc3003919.Vahrmeijer A.L., Hutteman M., van der Vorst J.R. et al. Image-guided cancer surgery using near-infrared fluorescence. Nat Rev Clin Oncol 2013;10(9):507-18. DOI: 10.1038/nrclinonc.2013.123.Fomina N., McFearin C.L., Sermsakdi M. et al. Low power, biologically benign NIR light triggers polymer disassembly. Macromolecules 2011;44(21):8590-7. DOI: 10.1021/ma201850q.Polom K., Murawa D., Rho Y.S. et al. Current trends and emerging future of indocyanine green usage in surgery and oncology: a literature review. Cancer 2011;117(21):4812-22. DOI: 10.1002/cncr.26087.Banerjee S.R., Foss C.A., Horhota A. et al. 111In- and IRDye800CW-labeled PLAPEG nanoparticle for imaging prostate-specific membrane antigen-expressing tissues. Biomacromolecules 2017;18(1):201-9. DOI: 10.1021/acs.biomac.6b01485.Baranski A.C., Schafer M., Bauder-Wust U. et al. PSMA-11-derived dual-labeled PSMA inhibitors for preoperative PET imaging and precise fluorescence-guided surgery of prostate cancer.J Nucl Med 2018;59:639-45. DOI: 10.2967/jnumed.117.201293.Schottelius M., Wurzer A., Wissmiller K. et al. Synthesis and preclinical characterization of the PSMA-targeted hybrid tracer PSMA-I&F for nuclear and fluorescence imaging of prostate cancer. J Nucl Med 2019;60(1):71-8. DOI: 10.2967/jnumed.118.212720.Hensbergen A.W., Buckle T., van Willigen D.W. et al. Hybrid tracers based on cyanine backbones targeting prostate-specific membrane antigen: tuning pharmacokinetic properties and exploring dye-protein interaction. J Nucl Med 2020;61(2):234-41. DOI: 10.2967/jnumed.119.233064.